Thermo Fisher (TMO) gains from strong end-market performances. International issues continue to hamper overall growth. The stock carries a Zacks Rank #3 (Hold) currently. Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produ ...